American Society for Pharmacy Law

Developments in Pharmacy Law Seminar XXIX







2018 ASPL Fall Meeting November 1-4, 2018

Hilton Head Marriott Resort & Spa Hilton Head Island, SC

ASPL is a nonprofit professional association for individuals with an interest in legal issues as they pertain to pharmacy, pharmaceuticals and related products and services. The ASPL annual seminar brings together over 250 industry professionals to share the most up-to-date, relevant and practical information.

Seminar goals include:

- Educate attendees on current and relevant information on wide-ranging pharmacy law issues.
- Provide pharmacy law educators with learning opportunities on the latest teaching methodologies and course curriculums relevant to pharmacy law education.
- Assist attendees with continuing education requirements through a program comprised of speakers and topics that offer 15 hours of continuing legal and pharmacy education credits to pharmacists, attorneys, pharmacistattorneys and pharmacy-law educators.

Register Today at www.aspl.org

American Society for Pharmacy Law

Developments in Pharmacy Law Seminar XXIX

2018 ASPL Fall Meeting November 1-4, 2018

Hilton Head Marriott Resort & Spa Hilton Head Island, SC

Accommodations:

A block of rooms at a discounted rate has been reserved for the ASPL



Seminar at the Hilton Head Marriott Resort & Spa. The resort is located at One Hotel Circle, Hilton Head Island, SC 29928. The discounted room rate is \$159 per night plus tax as long as you make your reservation by 5pm EST September 28, 2018. Make your reservation by calling the hotel at (888) 511-5086 or online. If calling, be sure to identify that you are with the ASPL 2018 conference so that you get the group rate.

Air Transportation:

The Marriott Hilton Head Resort & Spa is conveniently located 49 miles from the Savannah/Hilton Head International Airport (SAV).

Ground Transportation: ASPL will be providing free shuttle service from the Savannah/Hilton Head International Airport to the Hilton Head Marriott Resort to conference attendees and their quests. The shuttles will run on Thursday, November 1st from 11:00 am EDT to 6:00 pm EDT. The shuttles will only run to the Marriott Resort. Attendees will check-in with the transportation company at the airport baggage claim area. Free shuttles from the resort back to the airport will be available on Sunday, November 4th.

Taxis and rental cars are also available at the airport.

ACPE Continuing Education Credits

Participants may earn up to 15 contact hours (1.5 continuing education units) of Accreditation Council for Pharmacy Education (ACPE)-accredited continuing pharmacy education (CPE) credit. Sessions approved for CPE credit are listed with an ACPE universal activity number and number of continuing education units. To receive credit for successful completion for any activity, the participant must complete an attendance form and an activity evaluation form at the conclusion of the program. Verification of participation will be reported to the CPE tracking service, CPE Monitor, within 4 weeks after the program, and will then be accessible to participants at MyCPEMonitor.net.

You will need your NABP e-profile ID to note on your CE form so that it may be reported to CPE Monitor. If you have not yet obtained your NABP e-Profile ID, you may do so by visiting MyCPEMonitor. net, creating an e-Profile, and registering for CPE Monitor. Be sure to register for CPE Monitor to ensure that your e-Profile ID is fully activated.

The Washington State University WASHINGTON STATE College of Pharmacy is accredited by the Accreditation Council for Pharmacy



Education as a provider of continuing pharmacy education.

CPE now requires that all pharmacy continuing education (CE) credits must be processed and claimed no later than 60 days from the date of the live activity.



If you intend to apply for continuing legal education credits, please be sure to indicate the state (or states) in which

Quartes & Brady ILP

you are licensed and the corresponding license number(s) on the conference registration form. Quarles & Brady, LLP will process the CLE credits for the Developments in Pharmacy Law Seminar.

Continuing Legal Education credit will be applied for based on attendee return of the "Continuing Legal Education Credit Certificate of Attendance Form" at the conclusion of the seminar.

Register Today at www.aspl.org



2018 ASPL Fall Meeting

November 1-4, 2018

Hilton Head Marriott Resort & Spa Hilton Head Island, SC



Developments in Pharmacy Law Seminar XXIX

Thursday, November 1, 2018

3:00 PM - 5:00 PM	Registration Open
5:30 PM – 7:30 PM	ASPL Opening Reception

Friday, November 2, 2018

7:00 AM – 5:00 PM	Registration Open
7:00 AM – 8:00 AM	Breakfast
8:00 AM – 8:30 AM	Opening Welcome, Introduction of New Board

8:30 AM – 9:30 AM

Pharmacy Issues on The PBM's Radar/What Pharmacies can do About Pharmacy Benefit Manager Contract Terminations

0071-9999-18-027-L03-P (1.0 credit hours, 0.10 CEU*) Julie Letwat, JD, MPH, Faegre Baker Daniels LLP; Jay Warmuth, JD, Faegre Baker Daniels LLP; Bradley Wasser, JD, Duane Morris LLP; Jonathan Swichar, JD, Duane Morris LLP

"PBMs generally have discretion in deciding which pharmacies they will allow in their network, which pharmacies to re-enroll, and the events or circumstances which may lead to a pharmacy network termination. This presentation will discuss how pharmacies can successfully work with PBMs. Specifically, presenters will discuss key provisions in PBM contracts; handling re-enrollment questionnaires; typical grounds on which PBMs terminate pharmacy contracts; how a pharmacy should respond to a termination letter; and how a pharmacy can handle a PBM audit. In addition, we will discuss practices with respect to pharmacies that compound drugs and mail drugs to patients and what PBMs may consider questionable marketing and billing practices.

This session will also present on trending and current grounds upon which pharmacy benefit managers are relying on to terminate pharmacy providers from their provider networks. While the grounds are continually changing, often reflecting trends in pharmacy practices, operations and performance, reasons for terminations can range from poor audit performance, failure to timely report pharmacy board disciplinary actions, mailing medications, and of course fraudulent conduct contrary to PBMs' provider manuals and agreements. The presenters will discuss strategies and areas for operational improvements upon which pharmacies can avoid such terminations based on numerous grounds the PBMs rely on."

9:35 AM – 10:35 AM

Exploring the Drug Supply Chain Security Act: Implementation Issues & Impact on Pharmacy Practice

0071-9999-18-028-L03-P (1.0 credit hours, 0.10 CEU*) John S. Linehan, Esq., Epstein Becker Green; Christopher Smith, J.D., L.L.M. National Association of Chain Drug Stores (NACDS)

This presentation will summarize the Drug Supply Chain Security Act (DSCSA) structure, purpose, scope, and implementation history. Specific detail will be provided on pressing issues impacting stakeholders, including: federal preemption of state wholesaler and third-party licensing regulations; the functional scope and structure of the 2023 interoperable electronic data exchange; product verification processes; the feasibility of meeting statutory deadlines; and FDA guidance and the exercise of its enforcement discretion. The presentation will also examine past, present, and anticipated DSCSA challenges for pharmacies, most notably: bar code changes needed to accommodate serialization; the handling of FDA requests for information and recall investigations for suspect and illegitimate products; and error prevention and management with the anticipated use of aggregation and inference within the electronic data exchange. While examining these issues from the pharmacy's vantage, the presentation will explore applicable legal standards along with the operational challenges that stem from satisfying timely compliance. These issues are essential to pharmacy stakeholders seeking to minimize compliance risks while maximizing patient and business benefits under the recently-imposed DSCSA legal regime.

11:05 AM – 12:05 PM Controlled Substances 2018 - DEA and Industry Challenges

0071-9999-18-029-L03-P (1.0 credit hours, 0.10 CEU*) Karla L. Palmer, Director, Hyman, Phelps & McNamara, PC; Krista Tongring, Guide Post Solutions

In a moderated panel discussion, former DEA Trial Attorney and Office of Compliance Acting Section Chief Krista Tongring and Hyman Phelps & McNamara partner Karla Palmer review current actions and objectives of DEA and the broader health care industry manufacturers, distributors, pharmacies, and payors - to address the misuse and diversion of opioids and other controlled substances. In addition to reviewing regulatory requirements, the panel will discuss agency and judicial interpretations of the requirements, industry compliance programs, and the challenges both government and industry face. Ms. Tongring spent 20 years at the Department of Justice, including at the DEA. Among her various roles at the DEA, she led initiatives to improve DEA policies and procedures in the Office of Compliance and she litigated high-profile administrative actions involving DEA registrants for the Diversion and Regulatory Litigation Section. She is currently a Managing Director at Guidepost Solutions. Ms. Palmer represented Masters Pharmaceutical in recent litigation with DEA regarding suspicious order monitoring obligations of distributors, and she also represents many other industry segments. Barbara Rowland, ASPL board member and Post & Schell principal, will moderate the panel.

12:15 PM – 1:15 PM Lunch and Annual Meeting

1:30 PM – 2:30 PM The Last Line of Defense: Pharmacists' Corresponding Responsibility

0071-9999-18-030-L03-P (1.0 credit hours, 0.10 CEU*) Shannon F. Cox, J.D., King & Spalding; Larry Cote, Quarles & Brady LLP

In the "War on Opioids," the Drug Enforcement Administration and state agencies view pharmacists as the last line of defense against the diversion and abuse of controlled substances. This program is meant to assist pharmacies and pharmacists in navigating this critical and complex role. Presenters will review the legal framework for the concept of corresponding responsibility and examine how it has been interpreted and applied in regulatory enforcement actions. In addition, the session will focus on the practical implications of the concept of corresponding responsibility on the practice of pharmacy by identifying and discussing the "red flags" that regulators expect pharmacists to recognize and react to.

1:30 PM – 2:30 PM

Use of 42 USC 18122 Standard of Care, Federal and State Qualified Immunity Statutes As a Sword and Shield

0071-9999-18-031-L03-P (1.0 credit hours, 0.10 CEU*) Tamela J. White, BSN, JD, MPH, Farrell, White & Legg, PLLC; Erik Legg, Esq., JD, Farrell, White & Legg PLLC; Michael Farrell, BA, JD, Farrell, White & Legg, PLLC

The presentation and materials provided will address ways that pharmacists may utilize laws such as 42 USC 18122, the Standard of Care Practice Act and federal and state qualified immunity statutes to develop practice aides and litigation defense strategies. Physicians and prescribers enjoy certain degrees of insulation from civil liability arising from use of practice model criteria, protocols and FDA labeling. These laws have been enacted before pharmacists have enjoyed the every-increasing professional responsibilities and scope of duty obligations. These prescriber-oriented laws can be successfully used, however, in developing shared responsibility guidelines and collaborative practice agreements/guidelines. These laws can also be a valuable means to defend against claims of pharmacist negligence and/or licensure challenge. Because patient safety is a core component of this discussion, and there exists a potential gray area on the Venn diagram of intersection of the shared responsibility roles between pharmacist and prescriber, ethical challenges also exist when use prescriber defense tools in an offensive manner.

2:40 PM – 3:40 PM

Demystifying Buprenorphine Opiate Addiction Treatment

0071-9999-18-032-L03-P (1.0 credit hours, 0.10 CEU*) Ron Friedman, JD, Karr Tuttle Campbell; Rachael A. Ream, JD, PhD, Studebaker Nault, PLLC; Ken Egli, Doctor, Ideal Option. PLLC

Easing ourselves out of the current opiate epidemic will be no easy feat. One of the most highly regarded and promising forms of treatment is medication-assisted treatment (MAT) for opiate addiction. Buprenorphine, naltrexone, and methadone are approved by the FDA for MAT. Buprenorphine is being increasingly relied upon in our communities given evidence of its efficacy in controlling addiction and allowing patients to return to productive lives. The treatment itself, however, is often misunderstood, even by healthcare professionals, and the prescribing and dispensing of buprenorphine poses many regulatory challenges. The focus of this presentation will be to demystify MAT treatment, with an emphasis on the use of buprenorphine, and to discuss how the regulatory challenges are being met by prescribers and pharmacies. Topics will include: (1) What is medication-assisted treatment? How does buprenorphine treatment work and how does it compare to other forms of drug treatment for opiate addiction? Who may prescribe/ dispense? (2) DEA special compliance requirements regarding recordkeeping and inspections (3) How to cope with patient number limits imposed by regulation (4) Ryan Haight Act's potential application to the activities of treatment clinics (5) Addressing the unique privacy concerns of patients in addiction treatment (6) Funding and Payor challenges (7) Responding to common pharmacist inquiries/concerns regarding buprenorphine (pain vs. addiction treatment) and what a pharmacist should know (8) Responding to community concerns arising from operation of clinics (9) Addressing potential diversion of buprenorphine to opiate naïve patients (10) What is on the horizon for buprenorphine and emerging drug treatment?

2:40 PM – 3:40 PM

Drug Donation and Safety Net Pharmacy Programs: A Model for the Country

0071-9999-18-033-L03-P (1.0 credit hours, 0.10 CEU*) Alissa Smith, attorney, Dorsey & Whitney LLP; Jon Rosmann, SafeNetRx; Andrew Funk, PharmD, Iowa Board of Pharmacy

Every year over \$5 Billion in prescription drugs are wasted when long term care residents, patients, and others no longer need them. Prescription drug repositories reclaim unused medications and provide them to patients in need. Donated drugs are inspected by pharmacists and distributed to medical facilities or pharmacies to serve uninsured and underinsured patients with low incomes. SafeNetRx is a non-profit drug donation repository in Iowa that has worked collaboratively with the Iowa Board of Pharmacy, the Iowa Department of Public Health, and the Iowa Attorney General to be on the cutting edge of establishing and operating a prescription drug donation and safety net pharmacy program. In Iowa more than 78,000 people have been provided prescription drugs for free. Without a drug donation program, these individuals could have suffered life changing events and the medications would have been discarded; incinerated, flushed down the toilet, or simply tossed in the trash. The work being done in Iowa serves as a model for the many other states that are currently working to meet the needs

of vulnerable patients and appropriately dispose of medication waste. This session will be in the form of a panel that includes the CEO of SafeNetRx, legal counsel for SafeNetRx and the Executive Director of the Iowa Board of Pharmacy. The panelists will describe the legal and regulatory framework in which SafeNetRx operates its programs; discuss the role of pharmacists, pharmacies and providers; explore the operations of a drug donation program and other safety net programs that are implemented by SafeNetRx; and discuss creative solutions to operational, environmental, financial and legal challenges many states and health systems must address.

4:10 PM - 5:10 PM

Pharmacy DIR Fees: Past, Present, and Future

0071-9999-18-034-L03-P (1.0 credit hours, 0.10 CEU*) Stephanie Trunk, JD, Arent Fox, LLP; Jennifer Mallon, JD, National Community Pharmacists Association; Kala Shankle, JD, National Community Pharmacists Association

The concept of direct and indirect remuneration ("DIR") came into existence with the Medicare Part D in 2006 to capture retrospective rebates paid by pharmaceutical manufacturers to PBMs and Medicare Part D plans. Since that time, additional forms of DIR and DIR fees set forth in contracts between PBMs and Medicare Part D plans and pharmacies and manufacturers have exploded exponentially. In fact, DIR fees have grown so much that earlier this year the Trump Administration took interest in the fees as a possible area to consider in the Administration's push for lower prescription drug prices for patients. Pharmacy DIR fees, a smaller subset of total DIR fees, have equally gained notoriety as the Centers for Medicare & Medicaid Services also looks to lower patients' drug spend. Pharmacy DIR fees are retroactive price concessions, including among other things pay-toplay fees for network participation as well as periodic reimbursement reconciliations. As plan sponsors and PBMs continue to ratchet up the usage of these fees in their contracts, this timely presentation will focus on the impact of pharmacy DIR fees on the pharmacy industry.

Specifically, attendees can expect this presentation to focus on four learning objectives: 1) understanding the historical federal legislative and regulatory framework around DIR fees, and more specifically pharmacy DIR fees; 2) identifying the various types of pharmacy DIR fees and the terminology for pharmacy DIR fees and other retroactive fees; 3) assessing the impact of pharmacy DIR fees on plan sponsors, the government, and consumers; and finally 4) recognizing how legislators and regulators are or may address pharmacy DIR fees and other retroactive fees.

4:10 PM - 5:10 PM

Your Pharmacy is Being Audited by DEA – Complying, Defending, and Prevailing!

0071-9999-18-035-L03-P (1.0 credit hours, 0.10 CEU*) Natalia Mazina, JD; Mazina Law, Rx Healthcare Law Group; Dennis Wichern, MBA, Retired DEA Agent

This session will include the following information: Differences between DEA's administrative actions and criminal prosecution; and how to avoid the case being sent to the Department of Justice; Tips on negotiating a DEA settlement; Considerations affecting the decision to surrender the registration or continue with a hearing; Pharmacies' armed robberies, night burglaries, customer thefts, employee pilferage - prevention techniques; Common mistakes in controlled substances record-keeping; Trends in controlled substances state laws, comparison with federal law; Key components of risk management program and audit pla; DEA's arsenal to enforce the Controlled Substances Act, such as False Claims Act; Recent DEA cases against pharmacies, common patterns.

6:00 PM – 8:00 PM

Reception

Saturday, November 3, 2018

7:00 AM – 5:00 PM Registration Open

7:00 AM – 8:00 AM Breakfast

8:00 AM – 9:00 AM

Ethics in Pharmacy and Law: Practice implications of anti-discrimination standards in MRPC 8.4(g) and ACA section 1557

0071-9999-18-036-L03-P (1.0 credit hours, 0.10 CEU*) Jim Ruble PharmD, JD, University of Utah College of Pharmacy and School of Medicine

Societal norms are in substantial flux, and by most accounts, polarization of views and perspectives have intensified. Recent changes to the ABA model rules of professional conduct (i.e., Rule 8.4(g)), and a provision of the Affordable Care Act (i.e., section 1557) are mandates to the legal and pharmacy professions, respectively, about the need to treat persons fairly and to have practices that are transparent relative to how services are rendered. This presents an important opportunity to review and reflect on complying with ethical and professional tenets, while never forgetting that the very nature of the profession is to serve humanity. Using the pharmacy code of ethics and the Federal or ABA code of professional conduct along with philosophical principles, this program is designed to apply ethical principles to real or hypothetical cases. The audience will be a part of this program as they will apply the rules and principles to the cases presented using an ethical decision making algorithm to these cases the lawyers and pharmacist will each come to a decision - right or wrong.

This program will discuss and apply: (1) ABA Model Rules of Professional Conduct; (2) APhA Code of Ethics; (3) ACA Section 1557; (4) principles of conflict management; and (5) risk management.

9:05 AM – 10:05 AM

Information Technology in Pharmacy – Telepharmacy and Technology Issues in the Vertically Integrated Setting

0071-9999-18-037-L03-P (1.0 credit hours, 0.10 CEU*) Todd Nova, J.D., Hall Render

This presentation will include a detailed discussion of current information technology issues impacting the business and practice of pharmacy led by an attorney with national expertise focusing on interdisciplinary healthcare models for varied stakeholders including hospitals, pharmacies and physician practices in urban, rural and underserved community settings.

As both government and private payors continue to seek enhanced efficiencies, the role of pharmacies has continued to grow as an important tool to help achieve these goals. Additional expansion of value-based/bundled payments, specialty drugs and mail order pharmacy services has similarly enhanced the visibility of telepharmacy services. Together with ever-increasing vertical integration, information technology continues to grow in importance with respect to helping manage these complexities.

In discussing these issues, this presentation will discuss key information technology issues including data transfers in the hub and patient assistance program context, federal and state laws governing telepharmacy practice, billing and payment considerations and mechanisms for telepharmacy services and telepharmacy as an adjunct to provider practice. Additional attention will be paid to more traditional legal considerations in the information technology context, including data privacy/ security and software development/contracting.

10:05 AM – 10:35 AM Break

10:35 AM - 12:35 PM

Case Law Update

0071-9999-18-038-L03-P (2.0 credit hours, 0.20 CEU*) Roger Morris, RPh, JD, Quarles & Brady LLP; William Stilling, RPh, MS, JD, Kimball Legal

This annual summary provides pharmacists, compliance personnel, and attorneys an overview of the most important court decisions, lawsuits, and settlements from October 2017 to present. Presenters will address a variety of industry-specific civil and criminal liability issues, including pharmacy employment claims, False Claims Act cases and settlements, managed care and antitrust actions, state regulatory boards' authority to discipline licensees, and more.

12:35 PM – 2:00 PM Lunch On Own

2:00 PM – 4:05 PM Board of Pharmacy Mock Hearing and Appeal

0071-9999-18-039-L03-P (2.0 credit hours, 0.20 CEU*) Erika Gee, JD, Wright Lindsey Jennings; Luke Daniel, JD, Arkansas State Board of Pharmacy; Brenda McCrady, P.D., Arkansas State Board of Pharmacy

This presentation will cover an abbreviated version of the arc of the entire administrative disciplinary process for a case, beginning with an investigation by Board staff based on a complaint of diversion of controlled substances, proceeding to an informal settlement conference, a formal hearing and, finally, an appeal for judicial review. Ms. Gee routinely represents clients in front of the Arkansas Board, Mr. Daniel represents the Board and Dr. McCrady oversees investigations and enforcements for the Board, so the audience will hear a well-rounded presentation of this process from both sides.

Through a mock presentation of the informal settlement conference, the presenters will demonstrate the Board complaint/ investigative process, as well as the informal process used in Arkansas to determine whether a resolution can be reached without a formal hearing. In this instance, the mock respondent will not accept the committee's recommendation, and the matter will proceed to a formal hearing in front of the full Board. The presenters will proceed to a mock formal hearing, highlighting the differences between an administrative hearing and civil litigation.

Finally, the presenters will demonstrate the appeal process after a board hearing, focusing on the procedures used by the circuit court and the standard of review for an administrative appeal.

2:00 PM - 3:00 PM

Pharmacy Law Educators Session: Practical Considerations for Educators of Pharmacy Students to Prepare them for Compliance with Pharmacy Laws and Regulations

0071-9999-18-040-L03-P (1.0 credit hours, 0.10 CEU*) Virginia Herold, MS, CA State Board of Pharmacy This session will discuss ways that pharmacy law educators can orient students to pharmacy law and prepare them to maximize the benefit from their intern experience.

3:05 PM - 4:05 PM

Pharmacy Law Educators Session: Standard of Care Regulation and the Implications on Pharmacy Law Education

0071-9999-18-041-L03-P (1.0 credit hours, 0.10 CEU*) Jennifer L. Adams, PharmD, EdD, FAPhA, Idaho State University; Alex J. Adams, PharmD, MPH, Idaho State Board of Pharmacy When state Boards of Pharmacy and state legislatures pass new pharmacy rules and laws, pharmacy educators must react and update the content covered in pharmacy law, but what do educators do when your state Board of Pharmacy becomes the first state to regulate their pharmacists based on a standard of care? What should be considered in course modifications to appropriately cover standard of care regulation concepts? How might educators and regulators partner to appropriately educate PharmD students? Join us for a session that outlines what has been considered and modified in Idaho as we have navigated this transition.

Sunday, November 4, 2018

7:00 AM – 12:00 PM	Registration Open
--------------------	--------------------------

7:00 AM – 8:00 AM

8:00 AM – 9:00 AM

Substance Abuse in the Workplace - Attorneys & Pharmacist Ethics and Competence

Breakfast

0071-9999-18-042-L03-P (1.0 credit hours, 0.10 CEU*) Peter Gregorovic, JD, Esq., California Pharmacy Lawyers; Tony J. Park, PharmD, JD, California Pharmacy Lawyers; Ivan Petrzelka, PharmD, JD, MBA, California Pharmacy Lawyers

Many substance abuse presentations recite statistics and facts about lawyers or pharmacists who drink. But what about those in their respective profession who must deal with the substance impaired attorney or pharmacist who does not voluntarily seek help and is not compelled to get help? What should a colleague do if he or she reasonably believes they are observing an impaired co-worker affected by problems with substance abuse? What is the client or patient's role in addressing such a situation? This program will address these questions and discuss applicable laws and rules of professional conduct that may apply.

This seminar will also discuss how to detect signs and symptoms of substance abuse in the workplace. A sensitive workplace topic is the issue of detecting problems with substance abuse among your employees or co-workers. We will discuss simple and effective techniques for "reading" employees, co-workers and colleagues. This seminar will include methods and techniques discussed in Reading People (Dr. Wendy L. Patrick (Random House 2008). This seminar will also cover applicable laws and statistics regarding substance abuse, solutions for intervention, and effective training of employees in this area. This Seminar will cover topics of:

- How to "read" other people in and out of the office in order to catch the warning signs of a potential problem, by paying attention to the seven ways people project who they are and how they are likely to think and act.
- What laws or policies are implicated by having an employee with a substance abuse problem?
- How to spot and verify substance abuse both on the job and after hours.
- What substances are most commonly abused and how to detect the warning signs.
- Will legalized marijuana be the new 2 martini lunch.

9:05 AM - 10:05 AM

Precision Medicine - A Brave, New, Genomic World

0071-9999-18-043-L03-P (1.0 credit hours, 0.10 CEU*) Tamara (Tami) Millner, JD/PharmD, Vertex Pharmaceuticals

Advances in precision medicine have led to increased funding and necessitated additional regulatory guidance from the FDA. While precision medicine offers many benefits, several challenges remain. Pharmacy programs across the country seek to incorporate pharmacogenomics and precision medicine into their curricula. As a result of precision medicine, pharmacist training and the role of the pharmacist will undoubtedly evolve and pharmacists will assume an even more trusted role in patient care.

10:05 AM – 10:20 AM Break

10:20 AM - 11:20 AM

340B Drug Discount Program: Legislative and Regulatory Landscape and Key Compliance and Contractual Considerations for Contract Pharmacy Arrangements

0071-9999-18-044-L03-P (1.0 credit hours, 0.10 CEU*) Alan J. Arville, JD, Epstein Becker Green; Brenda Maloney Shafer, BSN, JD, LLM in Health Law, Quarles & Brady LLP

This program will discuss the latest 340B issues and developments impacting Covered Entities and Contract Pharmacies. Topics will include legislative and regulatory developments; the definition of eligible patient, Medicaid managed care duplicate discounts; current trends in HRSA contract pharmacy audit findings; best practices for self assessments and external compliance reviews; and business and contractual considerations for contract pharmacy arrangements.

12:00 PM – 3:00 PM ASPL Board Meeting

*Activity Type = Knowledge

NEW THIS YEAR - ASPL EVENT APP!

ASPL Conference Attendees will now be able to access up-to-date information on sponsors, attendees, and presentations throughout the conference with our new Event App. For those attendees wanting a hard copy of the conference materials, we are offering the purchase of the binder. Attendees will pick up their binder upon check-in at the conference registration desk. PLEASE NOTE: due to the production & shipping time of the binders, final copies of presentations may not be included. Binders will only be available onsite for those who have pre-ordered them. Binder purchase is \$20.

2018 ASPL Fall Meeting

November 1-4, 2018

Hilton Head Marriott Resort & Spa - Hilton Head Island, SC

LAST DAY TO PRE-REGISTER FOR SEMINAR - OCTOBER 19, 2018

Please print or type participant information exactly as you would like it to appear on your badge. Please use a separate form for each registrant.

N		🖵 Pharma	acist/Attorney
Name:		 🖬 Studen	ıt
Credentials: (i.e. RPh, JD, PharmD, etc.) _		 Technic	cian
For CLE Credit, please provide:		Deraleg	
Licensure State(s):	License #(s)	 Other_	
Company:			dicate which meals
Address:		you/gues	sts plan to attend:
City:		-	 Reception Breakfast
Phone: E-mail: _		 	LunchReception
Medically necessary dietary needs:		 Saturday	•
In case of emergency contact:		 Sunday	Breakfast
Phone:			

	I am a firs	t time ASPL	Conference	attendee
_	1 ann a m5		connerence	accentace

Registered guest(s): _____

□ I plan to attend the Saturday afternoon Pharmacy Law **Educators Session**

Registration fee for Seminar includes attendance at all seminar sessions, breakfast, refreshment breaks, Thursday and Friday receptions, Friday lunch and all seminar materials.

REGISTER BY SEPTEMBER 28 FOR EARLY BIRD DISCOUNT

FULL CONFERENCE:		Early	Late/Onsite
ASPL Member		\$625.00	\$725.00
Nonmember		\$755.00	\$855.00
Government Ra	ite*	\$450.00	\$450.00
Guest Spouse/Guest		\$280.00	\$280.00
Student		\$355.00	\$455.00
ONE DAY REGISTRATION:			
ASPL Member	🖵 Fri	\$355.00	\$455.00
	🗖 Sat or 🗖 Sun	\$230.00	\$330.00
Nonmember	🖵 Fri	\$425.00	\$525.00
	Sat or Sun	\$255.00	\$355.00
Student	🖵 Fri	\$230.00	\$330.00
	Sat or Sun	\$155.00	\$255.00
Binder		\$20.00	
	Total Fee	s:	

*Full time state or federal employee of government agency or education institution only.

NEW THIS YEAR - ASPL EVENT APP!

ASPL Conference Attendees will now be able to access up-to-date information on sponsors, attendees, and presentations throughout the conference with our new Event App. For those attendees wanting a hard copy of the conference materials, we are offering the purchase of the binder. Attendees will pick up their binder upon check-in at the conference registration desk. PLEASE NOTE: due to the production & shipping time of the binders, final copies of presentations may not be included. Binders will only be available onsite for those who have preordered them. Binder purchase is \$20.

Cancellation policy: Cancellations must be received in writing. You can email to administration@aspl.org. Your cancellation is null and void unless you receive confirmation of cancellation from the ASPL office. Refund of registration (less a \$50 administrative fee) will be granted for cancellations received in writing on or before September 28, 2018. Refund of registration (less a \$150 administrative fee) will be granted for cancellations received in writing after September 28, 2018 but on or before October 19, 2018. Refunds will not be granted for no-shows or cancellations received after October 19, 2018 regardless of cause. In the event of a no-show or cancellation after October 19, 2018, meeting materials will be forwarded to the address provided on your registration form.

Payment Method:

Check enclosed for full payment.

Please charge my:
MasterCard
Visa

Card Number: _____

Exp. Date: CVV#

Name on Card: _____

Signature: _____

Register on-line at www.aspl.org ASPL is accepting on-line registrations at www.aspl.org or, you can mail registration form to: ASPL - 3085 Stevenson Drive - Suite 200 - Springfield, IL 62703

or fax to: 217-529-9120.

Payment must accompany registration. Direct registration questions to Janet Bascom at jbascom@associationcentral.org or 217-529-6948

ASPL is a 501(c)(3) non-profit, voluntary professional association and all contributions are fully tax deductible. The ASPL Federal Tax ID Number is: 52-1250852.



Please indicate: Pharmacist

□ Attorney